Pilot Study Assessing the Feasibility and Impact of a Remote Adapted Physical Activity Program on Quality of Life in Patients With Inflammatory Bowel Disease (IBD)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorRaincy Montfermeil Hospital Group

About this trial

Inflammatory Bowel Disease (IBD) is a chronic relapsing condition that affects the gastrointestinal tract and is increasingly diagnosed in adolescents and young adults. Although anti-TNFα therapies are effective in reducing disease activity and improving quality of life, they are frequently associated with side effects such as fatigue, weight gain, and joint pain, which may be mitigated by regular physical activity.

Emerging evidence suggests that light to moderate physical activity may help reduce systemic and intestinal inflammation and improve IBD-related outcomes. However, access to structured physical activity programs remains limited, and personal or professional constraints may hinder participation.

This pilot study aims to assess the feasibility and impact of a remotely delivered Adapted Physical Activity (APA) program on the quality of life of patients with Inflammatory Bowel Disease (IBD), including Crohn's disease and ulcerative colitis. This study evaluates the effects of a 12-weeks remote APA intervention on quality of life as the primary outcome.

Secondary objectives include assessing changes in anxiety and depression, fatigue levels, IBD activity, and smoking behavior. The findings from this study may inform the development of scalable, non-pharmacological strategies to support symptom management and well-being in individuals with IBD.

Eligibility criteria

Qualifiers

Adults aged 18 years and older

Diagnosis of Inflammatory Bowel Disease (IBD) established for at least 6 months

Patient is motivated to participate in the Adapted Physical Activity (APA) program

Medical certificate confirming fitness to engage in remote physical activity

Disqualifiers

Patients under 18 years of age

Medical contraindication to physical activity

Total >1500 MET-min/week of vigorous activity on at least 3 days, OR

Total physical activity >3000 MET-min/week, regardless of distribution

Trial design

Treatments tested in this trial

  • adapted physical activity

Treatment groups

72 Participants
are divided into 1 treatment group

Sponsors and collaborators

Raincy Montfermeil Hospital Group

Lead sponsor

Janssen Cilag S.A.S.

Collaborator